Experience

Technion - Israel Institute of Technology

• Israel
• Higher Education
• 700 & Above Employee

• Principal Investigator

  • Aug 2008 - Present

• Professor

  • Aug 2008 - Present

  My team and I are developing practical ways which may lead to improved efficacy of conventional cancer therapies. The major anti-cancer drugs in the market are designed to kill tumor cells. However, little is done to target cells that support tumor growth. Our team is searching for targets identified in the patient which lead to tumor growth following cancer therapy. Identifying factors expressed in the patient but not in their tumors, and actively participating in tumor growth, may lead to improved clinical outcome of conventional treatments. This new approach is termed “host response to cancer therapy.” Show less


OncoHost
• Israel
• Hospitals and Health Care
• 1 - 100 Employee
• Co-Founder and Chief Scientific Advisor

  • Sep 2017 - Present

REMEDY CELL Ltd.
• Biotechnology Research
• 1 - 100 Employee
• Co-Founder and Chief Scientific Advisor at REMEDY CELL Ltd.

  • May 2020 - Present


Sunnybrook Health Sciences Centre

• Canada

• Postdoctoral Fellow

  • Sep 2002 - Jul 2008

  I was trained as a postdoctoral fellow in the laboratory of Dr. Robert Kerbel, studying circulating endothelial cells and their precursors subset (CEPs) as possible surrogate biomarkers to monitor biologic activity and determine the optimal biological dose of antiangiogenic drugs and treatment strategies, and the contribution of CEPs to tumor angiogenesis after treatment with various anti-cancer drugs. I was trained as a postdoctoral fellow in the laboratory of Dr. Robert Kerbel, studying circulating endothelial cells and their precursors subset (CEPs) as possible surrogate biomarkers to monitor biologic activity and determine the optimal biological dose of antiangiogenic drugs and treatment strategies, and the contribution of CEPs to tumor angiogenesis after treatment with various anti-cancer drugs.



Hebrew University of Jerusalem

• Israel
• Higher Education
• 300 - 400 Employee

• PHD Student

  • Aug 1997 - Aug 2002

  I was trained at the department of neurology at Hadassah University Hospital under the supervision of Prof. Ruth Gabizon. I studied the normal function of the prion protein. I was trained at the department of neurology at Hadassah University Hospital under the supervision of Prof. Ruth Gabizon. I studied the normal function of the prion protein.